Wafelman A R, Hoefnagel C A, Maes R A, Beijnen J H
Department of Pharmacy, Slotervaart Hospital, Amsterdam, The Netherlands.
Eur J Nucl Med. 1994 Jun;21(6):545-59. doi: 10.1007/BF00173043.
Since the introduction of radioiodinated metaiodobenzylguanidine in 1980, considerable research has been performed, both in the chemical field and in medical sciences. However, despite the wide use of radioiodinated metaiodobenzylguanidine, knowledge about its pharmacology is still limited. This paper reviews the biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry of radioiodinated metaiodobenzylguanidine. Iodine-131 metaiodobenzylguanidine therapy is in general well tolerated, but its effectiveness needs improvement. Also whole-body dosimetry as part of treatment planning needs to be improved. Future prospects on these items are included in this review.
自1980年放射性碘化间碘苄胍问世以来，化学领域和医学领域都开展了大量研究。然而，尽管放射性碘化间碘苄胍应用广泛，但其药理学知识仍然有限。本文综述了放射性碘化间碘苄胍的生物分布与药代动力学、药物相互作用、细胞毒性和剂量测定。碘-131间碘苄胍治疗总体耐受性良好，但其有效性有待提高。作为治疗计划一部分的全身剂量测定也需要改进。本文还包括了这些方面的未来展望。
